Treatment of follicular lymphomas using inhibitors of the LT pathway
View Patent ↗Therapeutic uses of inhibitors of the Lymphotoxin Pathway to treat tumors, specifically to treat follicular lymphomas.
1. A method for treating follicular lymphoma in a subject comprising administering an amount of a composition comprising a soluble lymphotoxin-beta receptor (LT-beta-R) and a pharmaceutically acceptable carrier, such that treatment occurs.
2. The method of claim 1 wherein the subject is a mammal.
3. The method of claim 2 wherein the subject is a human.
4. The method according to claim 1 wherein the soluble lymphotoxin-β receptor comprises a ligand binding domain that can selectively bind to a surface LT ligand.
5. The method of claim 1 , further comprising administering to said subject at least one chemotherapeutic agent.
6. The method of claim 1 , further comprising administering to said subject a radiation treatment.
7. The method of claim 1 further comprising administering to said subject a radiation treatment or bone marrow transplant.
8. The method of claim 1 , wherein the treatment is tumor regression or arrest.
9. The method of claim 1 , wherein the soluble LT-beta-R comprises a soluble LT-beta-R fused to one or more heterologous protein domains.
10. The method of claim 9 , wherein the soluble LT-beta-R is fused to a human immunoglobulin Fc domain.
11. The method of claim 1 , wherein the soluble LT-beta-R comprises an extracellular domain of LT-beta-R.
12. The method of claim 1 , wherein the soluble LT-beta-R is human LT-beta-R.
13. The method of claim 12 , wherein the soluble LT-beta-R further comprises a human immunoglobulin Fc domain.
14. The method of claim 13 , wherein the immunoglobulin is IgG1.
15. A method for disrupting interaction of a B cell lymphoma with its environment in a subject, comprising administering to the subject a composition comprising a soluble LT-beta-R and a pharmaceutically acceptable carrier, such that disruption of the interaction of the B cell lymphoma with its environment occurs.
16. The method of claim 15 , wherein the interaction is between the B cell lymphoma and a follicular dendritic cell in the subject.
17. The method of claim wherein the disruption of the interaction results in inhibition of growth of the B cell lymphoma.
18. The method of claim 15 , wherein the soluble LT-beta-R comprises a soluble LT-beta-R fused to one or more heterologous protein domains.
19. The method of claim 18 , wherein the heterologous protein domain comprises a human immunoglobulin Fc domain.
20. The method of claim 15 , wherein the soluble LT-beta-R comprises an extracellular domain of LT-beta-R.
21. The method of claim 15 , wherein the soluble LT-beta-R is human LT-beta-R.
22. The method of claim 21 , wherein the LT-beta-R-immunoglobulin fusion comprises a human immunoglobulin Fc domain.
23. The method of claim wherein the immunoglobulin is IgG1.
24. A method for treating follicular lymphoma in a human subject, the method comprising administering to the subject a pharmaceutical composition comprising a polypeptide that comprises a soluble, ligand-binding domain of human lymphotoxin-beta receptor (LT-beta-R) fused to a human IgG1 Fc domain, such that treatment occurs.
25. The method of claim 24 , wherein the soluble, ligand-binding domain of human LT-beta-R comprises SEQ ID NO:1.